In ammation is recognised as an important contributor to Alzheimer's disease (AD) pathogenesis alongside extracellular deposits of amyloid β protein (Aβ) and intraneuronal deposits of hyper-phosphorylated tau protein. Microglia are the key component of innate immunity within the central nervous system, and the source of in ammation in the brain. The amyloid cascade hypothesis places Aβ at a key point in the pathogenesis of AD. Consequently, immunisation against Aβ is a promising experimental treatment for AD. The current study presents a neuropathological follow-up of a unique cohort of AD patients who took part in the active Aβ42 immunisation clinical trial (AN1792, Elan) and in whom reduction in Aβ load had been observed. The hypothesis of the study is that Aβ42 immunisation affects the microglial activation level and profile associated with the reduction in Aβ. Levels of the microglial markers indicative of specific microglial functions, the microglial receptors involved in antigen recognition and uptake, complement component C1q, IgG, Aβ42 and phospho-tau in the brain tissue (frontal, temporal and parietal lobes) of immunised (n=11) and non-immunised (n=28) AD patients were analysed using immunohistochemistry. In immunised brain, a two-fold reduction in Fc receptor I (P=0.001) and Fc receptor II (P=0.002), a ten-fold reduction in macrophage scavenger receptor A (P <0.001), and a 40% reduction in lysosomal glycoprotein CD68 (P=0.018) compared to non-immunised brain were observed. Similarly, Aβ42 and phospho-tau levels were also decreased by 80% and 40% respectively. No changes in the microglial activation and antigen-presentation receptor HLA-DR, calcium-adapter channel Iba-1, or the levels of IgG and C1q were detected. The load of all microglial markers, IgG and C1q correlated with the phospho-tau load in non-immunised cases. In addition, Iba-1 and Fc RII load inversely correlated with Aβ42 load in the non-immunised group. These correlations no longer held in the immunised group. Instead, a positive correlation between the number of MSR-A positive microglial clusters and Aβ42, and an inverse correlation between C1q and Aβ42 were noted in immunised AD cases. The current study is the first of its kind in presenting a detailed immunohistochemical profile of microglia in human AD and following active Aβ42 immunisation treatment. In addition, a consistent and reproducible method for automated microscopy image analysis was developed as part of this project contributing to research methodologies. The results support the changes in the level and profile of microglial activation implied by the hypothesis. The data also suggest a link between immune system activation and the tau pathology in AD. The ability of microglia to change their profile and switch targets following stimulation by active immunisation is demonstrated in human brain.
| Identifer | oai:union.ndltd.org:bl.uk/oai:ethos.bl.uk:568885 |
| Date | January 2012 |
| Creators | Zotova, Elina |
| Contributors | Nicoll, James ; Boche, Delphine |
| Publisher | University of Southampton |
| Source Sets | Ethos UK |
| Detected Language | English |
| Type | Electronic Thesis or Dissertation |
| Source | https://eprints.soton.ac.uk/347858/ |
Page generated in 0.0026 seconds